(Q38261285)

1 September 2017

1 reference

title

The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer (English)

1 reference

1 September 2017

1 reference

Laura S van Dam

1

1 reference

PubMed ID

25327979

1 September 2017

Verena M de Zwart

series ordinal

2

1 reference

PubMed ID

25327979

1 September 2017

Friederike A G Meyer-Wentrup

series ordinal

3

1 reference

1 September 2017

18 October 2014

1 reference

1 September 2017

Pediatric Blood Cancer

1 reference

1 September 2017

62

1 reference

1 September 2017

2

1 reference

1 September 2017

190-197

1 reference

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

1 September 2017

1 reference

The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

21 January 2018

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

NFATc1 regulates PD-1 expression upon T cell activation.

21 January 2018

1 reference

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

21 January 2018

1 reference

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

21 January 2018

1 reference

PD-1/PD-L pathway and autoimmunity

21 January 2018

1 reference

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

21 January 2018

1 reference

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia

21 January 2018

1 reference

Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.

21 January 2018

1 reference

21 January 2018

1 reference

Immunosuppressive microenvironment in neuroblastoma

21 January 2018

1 reference

B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence

21 January 2018

1 reference

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.

21 January 2018

1 reference

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas

21 January 2018

1 reference

Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.

21 January 2018

1 reference

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

21 January 2018

1 reference

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

21 January 2018

1 reference

In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.

21 January 2018

1 reference

Features of responding T cells in cancer and chronic infection.

21 January 2018

1 reference

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Immune modulation in cancer with antibodies

21 January 2018

1 reference

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1002/PBC.25284

1 reference

1 September 2017

1 reference

PubMed ID

25327979